Background: The reduction in plasma LDL-C concentrations with 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitor (statin) therapy has been reported to reduce cardiovascular …

BACKGROUND: A manufacturer of atorvastatin is seeking marketing approval in Korea of a
generic product for adult patients with primary hypercholesterolemia. OBJECTIVE: The …

Background Although accumulating evidence suggests a more extensive reduction of low-
density lipoprotein cholesterol (LDL-C), it is unclear whether a higher statin dose is more …

Lowering of serum cholesterol levels by pharmacologic intervention with statins reduces the
incidence of cardiovascular events in subjects with and without atherosclerotic …

Background and Objectives Although the rate of prescribing hydroxylmethyglutaryl-CoA
reductase inhibitors (statin) has recently increased, there is a large treatment gap between …

Purpose: The American College of Cardiology/American Heart Association (ACC/AHA)
guidelines are based on studies with a limited number of Asian subjects; therefore, they are …

Background The ability of statins to reduce LDL-c plays an important role in both primary
and secondary prevention of atherosclerotic cardiovascular diseases. Such treatment can …

The objective of this multicenter, randomized, open-label, parallel-group, 8-week study was
to evaluate the comparative dose efficacy of the 3-hydroxy-3-methylglutaryl coenzyme A …

Background: Coronary heart disease (CHD) is the number one cause of death in Western
societies. Elevated levels of plasma low-density lipoprotein (LDL) cholesterol and triglycer …

Background and Purpose: There have been few reports on the efficacy and safety of statins
in the Asian population. The study objectives were to compare the efficacy and safety of …